litlas
Log inCreate account

Nageatte Ibrahim

Active 2008–2024

52
Papers
23,626
Citations
42
h-index
51
i10-index

Citations

Citations per year for Nageatte Ibrahim1945: 1 citations1997: 1 citations2001: 1 citations2005: 1 citations2009: 3 citations2010: 16 citations2011: 7 citations2012: 15 citations2013: 110 citations2014: 177 citations2015: 235 citations2016: 372 citations2017: 413 citations2018: 400 citations2019: 1,336 citations2020: 1,643 citations2021: 1,579 citations2022: 1,241 citations2023: 833 citations2024: 1,163 citations2025: 453 citations2026: 11 citations1946–1996: no citations, so these years are not shown1998–2000: no citations, so these years are not shown2002–2004: no citations, so these years are not shown2006–2008: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,475 citing papers, 26% of this breakdownChina: 1,530 citing papers, 11.5% of this breakdownItaly: 801 citing papers, 6% of this breakdownGermany: 770 citing papers, 5.8% of this breakdownUnited Kingdom: 710 citing papers, 5.3% of this breakdownFrance: 707 citing papers, 5.3% of this breakdownAustralia: 660 citing papers, 4.9% of this breakdownNetherlands: 452 citing papers, 3.4% of this breakdownCanada: 411 citing papers, 3.1% of this breakdownSpain: 401 citing papers, 3% of this breakdownSwitzerland: 380 citing papers, 2.8% of this breakdownJapan: 361 citing papers, 2.7% of this breakdown
0%26%Other 20.2%

Institutions

Fields

  • Medicine68.9%
  • Biochemistry, Genetics and Molecular Biology21.2%
  • Immunology and Microbiology6.7%
  • Engineering0.9%
  • Computer Science0.4%
  • Mathematics0.4%
  • Other1.5%

Topics

  • Cancer Immunotherapy and Biomarkers19.3%
  • Immunotherapy and Immune Responses7.6%
  • Melanoma and MAPK Pathways6.9%
  • CAR-T cell therapy research6.2%
  • Cutaneous Melanoma Detection and Management4.9%
  • Immune Cell Function and Interaction2.6%
  • Other52.5%

Coauthors

All papers

Open in search
  1. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Authors: Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas - New England Journal of Medicine 2015 cited by 5,847

  2. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    Authors: Răzvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer H. Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn, Chunsheng Zhang, Jared Lunceford, Andrew K. Joe, Jonathan D. Cheng, Andrea L. Webber, Nageatte Ibrahim, Elizabeth R. Plimack, Patrick A. Ott, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan, Joanne E. Tomassini, Andrey Loboda, David R. Kaufman - Science 2018 cited by 2,380

  3. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert - New England Journal of Medicine 2018 cited by 1,853

  4. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Authors: Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V. Long - The Lancet Oncology 2019 cited by 1,153

  5. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

    Authors: Jason J Luke, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Muhammad A Khattak, Dirk Schadendorf, Georgina V Long, Paolo A Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Jean-Jacques Grob, Caroline Robert, Matteo S Carlino, Peter Mohr, Andrew Poklepovic, Vernon K Sondak, Richard A Scolyer, John M Kirkwood, Ke Chen, Scott J Diede, Sama Ahsan, Nageatte Ibrahim, Alexander M M Eggermont - The Lancet 2022 cited by 477

  6. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

    Authors: Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen‐Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Mitchell, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Qi Zhao, E. Jensen, S. Ahsan, Nageatte Ibrahim, Antoni Ribas - Annals of Oncology 2019 cited by 944

  7. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Authors: Keith T. Flaherty, J. Infante, Adil Daud, René González, Richard Kefford, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Igor Puzanov, Peter F. Lebowitz, Ajay P. Singh, Shonda M Little, Peng Sun, Alicia J. Allred, Danièle Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey S. Weber - New England Journal of Medicine 2012 cited by 2,798

  8. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Authors: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert - The Lancet 2017 cited by 1,239

  9. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  10. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

    Authors: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Caroline Robert, Stefan Suciu - JAMA Oncology 2020 cited by 436

  11. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert - Journal of Clinical Oncology 2020 cited by 281

  12. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

    Authors: Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Phillip Friedlander, Adil Daud, Harriet M. Kluger, Sunil Reddy, Brian C. Boulmay, Adam I. Riker, Melissa Burgess, Brent A. Hanks, Thomas Olencki, Kim Margolin, Lisa Lundgren, Abha Soni, Nirasha Ramchurren, Candice D. Church, Song Y. Park, Michi M. Shinohara, Bob Salim, Janis M. Taube, Steven Bird, Nageatte Ibrahim, Steven P. Fling, Blanca Homet Moreno, Elad Sharon, Martin A. Cheever, Suzanne L. Topalian - Journal of Clinical Oncology 2019 cited by 390

  13. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

    Authors: Antoni Ribas, Donald P. Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H. Miller, Matteo S. Carlino, Rosalie Fisher, Georgina V. Long, F. Stephen Hodi, Jennifer Tsoi, Catherine S. Grasso, Bijoyesh Mookerjee, Qing Zhao, Razi Ghori, Blanca Homet Moreno, Nageatte Ibrahim, Omid Hamid - Nature Medicine 2019 cited by 326

  14. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

    Authors: Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khushalani, Justine V. Cohen, Elizabeth I. Buchbinder, Kari Kendra, Pauline Funchain, Karl D. Lewis, Robert M. Conry, Bartosz Chmielowski, Ragini R. Kudchadkar, Douglas B. Johnson, Hongli Li, James Moon, Zeynep Eroglu, Brian Gastman, Magdalena Kovacsovics-Bankowski, Krishna S. Gunturu, Scot W. Ebbinghaus, Sama Ahsan, Nageatte Ibrahim, Elad Sharon, Larissa A. Korde, John M. Kirkwood, Antoni Ribas - Cancer Discovery 2021 cited by 102

  15. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

    Authors: Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Tara C. Mitchell, Peter Hersey, Roxana Dronca, Richard W. Joseph, C. Boutros, Le Min, Georgina V. Long, Jacob Schachter, Igor Puzanov, Reinhard Dummer, Jianxin Lin, Nageatte Ibrahim, Scott J. Diede, Matteo S. Carlino, Anthony M. Joshua - European Journal of Cancer 2020 cited by 100

  16. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

    Authors: F. Stephen Hodi, Donald P. Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada, Wanyong Zeng, Anita Giobbie‐Hurder, Michael B. Atkins, Nageatte Ibrahim, Philip Friedlander, Keith T. Flaherty, Gëorge F. Murphy, Scott J. Rodig, Elsa F. Velázquez, Martín C. Mihm, Sara E. Russell, Pamela J. DiPiro, Jeffrey T. Yap, Nikhil H. Ramaiya, Annick D. Van den Abbeele, Maria Gargano, David F. McDermott - Cancer Immunology Research 2014 cited by 604

  17. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Authors: Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar‐Sela, Félix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas - Nature Medicine 2019 cited by 323

  18. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

    Authors: Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, Enrique Grande, Jean‐Pierre Delord, Ronnie Shapira‐Frommer, Emily K. Bergsland, Manisha H. Shah, Marwan Fakih, Shunji Takahashi, Sarina A. Piha‐Paul, Bert H. O’Neil, Sajeve Thomas, Martijn P. Lolkema, Menghui Chen, Nageatte Ibrahim, Kevin Norwood, Julien Hadoux - Clinical Cancer Research 2020 cited by 221

  19. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

    Authors: Omid Hamid, Caroline Robert, Antoni Ribas, F. Stephen Hodi, Euan Walpole, Adil Daud, Ana S. Arance, Ewan Brown, Christoph Höeller, Laurent Mortier, Jacob Schachter, Jianmin Long, Scot Ebbinghaus, Nageatte Ibrahim, Marcus O. Butler - British Journal of Cancer 2018 cited by 174

  20. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

    Authors: Diwakar Davar, Hong Wang, Joë-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Mignane Ka, Carmine Menna, Amy Rose, Cindy Sander, Amir A. Borhani, Arivarasan Karunamurthy, Ahmad A. Tarhini, Hussein A. Tawbi, Qing Zhao, Blanca Homet Moreno, Scott Ebbinghaus, Nageatte Ibrahim, John M. Kirkwood, Hassane M. Zarour - Journal of Clinical Oncology 2018 cited by 83

  21. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

    Authors: Anthony W. Tolcher, Razelle Kurzrock, V. Valero, René González, Rebecca S. Heist, Antoinette R. Tan, Julie Means‐Powell, Theresa L. Werner, Carlos Becerra, Chenxi Wang, Cathrine Leonowens, Shanker Kalyana‐Sundaram, Joseph F. Kleha, Jennifer Gauvin, Anthony M. D’Amelio, Catherine Ellis, Nageatte Ibrahim, Yan Li - Cancer Chemotherapy and Pharmacology 2020 cited by 58

  22. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

    Authors: Georgina V. Long, Victoria Atkinson, Jonathan Cebon, Michael B. Jameson, Bernie Fitzharris, Catriona M. McNeil, Andrew Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander M. Menzies, Alexander Guminski, Richard Kefford, Benjamin Y. Kong, Babak Tamjid, Archana Srivastava, Anna J. Lomax, Mohammed Rafiqul Islam, Xinxin Shu, Scot Ebbinghaus, Nageatte Ibrahim, Matteo S. Carlino - The Lancet Oncology 2017 cited by 246

  23. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

    Authors: Omid Hamid, Igor Puzanov, Reinhard Dummer, Jacob Schachter, Adil Daud, Dirk Schadendorf, Christian U. Blank, Lee D. Cranmer, Caroline Robert, Anna C. Pavlick, René González, F. Stephen Hodi, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Tara C. Gangadhar, Ziwen Wei, Scot Ebbinghaus, Nageatte Ibrahim, Antoni Ribas - European Journal of Cancer 2017 cited by 180

  24. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, James Larkin, Paul Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Thierry Lesimple, Michele Maio, Gerald P. Linette, Laurent Mortier, Inge Marie Svane, Jacob Schachter, Michael P. Brown, Peter Hersey, Catherine Barrow, Ragini R. Kudchadkar, Caroline Dutriaux, Xinni Song, Pietro Quaglino, Paola Queirolo, Friedegund Meier, Daniil Stroyakovskiy, B. Guillot, Pablo L. Ortiz‐Romero, Lars Bastholt, Claus Garbe, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Carmen Loquai, Frank Meiß, Vanna Chiarion‐Sileni, Gil Bar‐Sela, Bernard M. Fitzharris, Philippe Saïag, Jean‐Philippe Arnault, Jan‐Christoph Simon, Rosalie Stephens, Jean‐François Baurain, Célèste Lebbé, P. Combemale, Reinhard Dummer, Axel Hauschild, Phillip Parente, Naoya Yamazaki, Mohammed Milhem, M.‐T. Leccia, L. Geoffrois, Lutz Kretschmer, Elaine Dunwoodie, John Walker, Michal Lotem, Daniel Hendler, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Marcin Dzienis, Geke A.P. Hospers, Marco Siano, Jessica C. Hassel, Philippa Corrie, Maria-Jose Passos, Max Levin, Christoph Höeller, L. Machet, Sigrun Hallmeyer, Ashita Waterston, V. Descamps, Felix Kiecker, Maureen J.B. Aarts, Henrik Schmidt and 34 more - The Lancet Oncology 2021 cited by 72